Basilea Pharmaceutica (LTS:0QNA) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QNA Basilea Pharmaceutica Ltd LTS:0QNA
65 GF Score
Price CHF54.20
GF Value CHF58.25
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Basilea Pharmaceutica Quality Rank Related Terms

LTS:0QNA
65GF Score
Basilea Pharmaceutica Ltd LTS:0QNA
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Basilea Pharmaceutica (LTS:0QNA) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.20 is trading 7% below its estimated GF Value™ of CHF58.25. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for LTS:0QNA:

  • Quality Rank:
  • GF Value™: CHF58.25 vs. price of CHF54.20 (7% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the LTS:0QNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
65GF Score

Get the complete analysis for LTS:0QNA

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.20
Price
CHF58.25
GF Value